Opportunity Information: Apply for RFA CK 09 002
Apply for RFA CK 09 002
- The Centers for Disease Control and Prevention in the health sector is offering a public funding opportunity titled "A Creutzfeldt Jakob Disease (CJD) Lookback Study Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt Jakob Disease (U01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.283 Centers for Disease Control and PreventionInvestigations and Technical Assistance.
- This funding opportunity was created on Apr 13, 2009 and posted on Feb 11, 2009.
- Applicants must submit their applications by Apr 27, 2009 Applications due 500pm Eastern Time on closing date. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $475,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $93,000.00 in funding.
- The number of recipients for this funding is limited to 1 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
- American Red Cross (ARC)
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This funding opportunity, titled "A Creutzfeldt Jakob Disease (CJD) Lookback Study Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt Jakob Disease (U01)," was issued by the Centers for Disease Control and Prevention (CDC) through its Procurement and Grants Office. It is structured as a cooperative agreement (U01), which typically means the funded recipient would carry out the project while working closely with CDC staff who may provide substantial programmatic involvement, technical input, and coordination. The overall focus sits in the public health and health investigations space, specifically addressing transfusion safety and the potential for transmission of rare but devastating neurologic disease through blood products.
The purpose of the announcement is to continue a long-running, active nationwide "lookback" study that originally began in 1995. In a lookback study design, investigators start with donors who are later found to have a particular condition, then trace and monitor people who received blood or blood components from those donors. Here, the condition of interest is the classic forms of Creutzfeldt Jakob Disease, a fatal human prion disease. The study aims to determine whether there is evidence that classic CJD can be transmitted via blood transfusion, by following recipients of blood products from donors who were subsequently diagnosed with classic CJD and assessing outcomes in those recipients. The underlying public health value is straightforward: if even a small transfusion-transmission risk exists, the findings could influence donor screening policies, product management practices, surveillance approaches, and risk communication for the blood supply.
Financially, the announcement anticipated supporting a single award. It indicated that approximately 92,000 dollars would be available in fiscal year 2009 for that award, with an award ceiling listed at 93,000 dollars and no stated minimum award floor. The broader estimated total funding for the project period is listed as 475,000 dollars, which suggests the cooperative agreement may span multiple years with continued support contingent on annual appropriations and satisfactory progress. The opportunity does not require cost sharing or matching funds, meaning the recipient would not be expected to contribute a defined portion of project costs from non-federal sources as a condition of the award.
Eligibility is narrowly defined. The eligible applicant specified is the American Red Cross (ARC), with the listing classifying applicants as "Others" but clarifying ARC in the eligibility information. In practical terms, that means this was not a broadly competed solicitation for universities, hospitals, or state health departments; it was effectively targeted to the organization positioned to conduct national blood donor lookback activities at scale, with access to relevant donor and recipient tracing capabilities and operational data systems.
Administratively, the funding opportunity number is RFA-CK-09-002, and it is associated with CFDA number 93.283 (CDC Investigations and Technical Assistance). The opportunity was posted on February 11, 2009. The original closing date was April 13, 2009, with the current closing date extended to April 27, 2009. Applications were due by 5:00 pm Eastern Time on the closing date. The archive date is listed as May 13, 2009, which generally indicates when the opportunity was removed from active listing after the application window closed.
For applicants or interested parties who had trouble accessing the full announcement, the contact provided was CDC PGO TIMS, with a phone number (770-488-2700) and a general email contact, along with an additional information link pointing to the CDC funding opportunity announcement listing. Overall, the announcement describes a continuation award designed to sustain a specialized national surveillance and follow-up effort to answer a specific transfusion safety question: whether classic CJD poses a blood-borne transmission risk when donors later develop the disease, as measured through systematic tracking and outcome assessment among blood product recipients.
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The funding opportunity is titled "A Creutzfeldt Jakob Disease (CJD) Lookback Study Assessing the Risk of Blood Borne Transmission of Classic Forms of Creutzfeldt Jakob Disease (U01)."
Which agency issued this opportunity?
This opportunity was issued by the Centers for Disease Control and Prevention (CDC) through its Procurement and Grants Office.
What type of funding mechanism is being used?
The award is structured as a cooperative agreement (U01). In a cooperative agreement, the recipient conducts the project while CDC staff may have substantial involvement, including programmatic input, technical support, and coordination.
What is the main public health focus of the project?
The project sits in public health and health investigations, with a specific focus on transfusion safety and evaluating whether a rare but severe neurologic disease (classic CJD) could be transmitted through blood products.
What is the purpose of the CJD lookback study?
The purpose is to continue an active nationwide lookback study that began in 1995 to determine whether there is evidence that classic forms of Creutzfeldt Jakob Disease (CJD) can be transmitted via blood transfusion.
What does "lookback study" mean in this context?
In this lookback design, investigators start with blood donors who are later found to have a condition (here, classic CJD), then trace and monitor individuals who received blood or blood components from those donors to assess outcomes.
What disease is being studied?
The condition of interest is the classic forms of Creutzfeldt Jakob Disease (CJD), described as a fatal human prion disease.
Who would be followed or monitored as part of the study?
The study follows recipients of blood products from donors who were subsequently diagnosed with classic CJD, and it assesses outcomes in those recipients.
Why is this study important for the blood supply?
If even a small transfusion-transmission risk exists, results could influence donor screening policies, blood product management practices, surveillance approaches, and risk communication related to the safety of the blood supply.
How many awards were anticipated?
The announcement anticipated supporting a single award.
How much funding was expected to be available?
Approximately $92,000 was expected to be available in fiscal year 2009 for the single award.
What is the award ceiling?
The award ceiling listed in the announcement is $93,000.
Is there a minimum award amount stated?
No minimum award floor is stated in the information provided.
What is the estimated total funding over the project period?
The broader estimated total funding for the project period is listed as $475,000, suggesting a multi-year effort with continued support depending on annual appropriations and satisfactory progress.
Is cost sharing or matching required?
No. The opportunity does not require cost sharing or matching funds.
Who is eligible to apply?
Eligibility is narrowly defined. The eligible applicant specified is the American Red Cross (ARC). While the listing classifies applicants as "Others," it clarifies that ARC is the eligible applicant in the eligibility information.
Is this a broadly competed solicitation for multiple organizations?
No. Based on the eligibility description, it was effectively targeted to the American Red Cross rather than broadly open to universities, hospitals, or state health departments.
What is the funding opportunity number?
The funding opportunity number is RFA-CK-09-002.
What CFDA number is associated with this opportunity?
The opportunity is associated with CFDA number 93.283 (CDC Investigations and Technical Assistance).
When was the opportunity posted?
The opportunity was posted on February 11, 2009.
What was the original closing date?
The original closing date was April 13, 2009.
Was the closing date extended?
Yes. The current closing date was extended to April 27, 2009.
What time were applications due on the closing date?
Applications were due by 5:00 pm Eastern Time on the closing date.
What is the archive date and what does it indicate?
The archive date is listed as May 13, 2009. This generally indicates when the opportunity was removed from active listing after the application window closed.
Who can be contacted for help accessing the full announcement?
The contact provided is CDC PGO TIMS. The phone number listed is 770-488-2700, and a general email contact is also provided, along with an additional information link pointing to the CDC funding opportunity announcement listing.
Does the announcement describe the work as a continuation effort?
Yes. The announcement describes a continuation award intended to sustain a specialized nationwide surveillance and follow-up effort that has been active since 1995.
What core question is the study trying to answer?
The central question is whether classic CJD poses a blood-borne transmission risk when donors later develop the disease, as measured through systematic tracking and outcome assessment among blood product recipients.
Browse more opportunities from the same category: Health
Next opportunity: NIJ FY09 Social Science Research in Forsensic Science
Previous opportunity: Organ Transplant Infection Detection and Prevention Program (U01)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CK 09 002
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CK 09 002) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Quality Improvement/Management Technical Assistance Center Cooperative Agreement Apply for HRSA 09 120 Funding Number: HRSA 09 120 Agency: Health Resources and Services Administration Category: Health Funding Amount: $1,500,000 |
| Occupational Safety and Health Research (R01) Apply for PA 07 318 Funding Number: PA 07 318 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Alcohol, Decision Making and Adolescent Brain Development (R21) Apply for PA 09 096 Funding Number: PA 09 096 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Alcohol, Decision Making, and Adolescent Brain Development (R01) Apply for PA 09 097 Funding Number: PA 09 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NCMHD Health Disparities Research on Minority and Underserved Populations (R01) Apply for RFA MD 09 004 Funding Number: RFA MD 09 004 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| Surveillance and Response to Avian and Pandemic Influenza Apply for CDC RFA IP09 902 Funding Number: CDC RFA IP09 902 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $300,000 |
| Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS (R01) Apply for RFA AA 09 007 Funding Number: RFA AA 09 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alcohol Pharmacotherapy and the Treatment and Prevention of HIV/AIDS (R03) Apply for RFA AA 09 008 Funding Number: RFA AA 09 008 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NHLBI Career Transition Award (K22) Apply for PAR 09 102 Funding Number: PAR 09 102 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Targeted Rural Health Research Grant Program Apply for HRSA 09 167 Funding Number: HRSA 09 167 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Drug Free Communities Mentoring Program Apply for SP 09 003 Funding Number: SP 09 003 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $75,000 |
| National Center for Construction Safety and Health (U60) Apply for RFA OH 09 001 Funding Number: RFA OH 09 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Grants to States for Loan Repayment Apply for HRSA 09 205 Funding Number: HRSA 09 205 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Initiative for Maximizing Student Development (IMSD) (R25) Apply for PAR 09 104 Funding Number: PAR 09 104 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Tools Technologies for Assessing Manual Therapies (SBIR R43/R44) Apply for RFA AT 09 003 Funding Number: RFA AT 09 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Womens Mental Health and Sex/Gender Differences Research (R01) Apply for PA 09 108 Funding Number: PA 09 108 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Womens Mental Health and Sex/Gender Differences Research (R21) Apply for PA 09 109 Funding Number: PA 09 109 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Translating Research to Protect Health through Health Promotion, Prevention, and Preparedness (R18) Apply for RFA CD 09 001 Funding Number: RFA CD 09 001 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $450,000 |
| AHRQ Research Infrastructure Program Phase II Limited Competition (R24) Apply for RFA HS 09 001 Funding Number: RFA HS 09 001 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Alzheimers Disease Core Centers (P30) Apply for RFA AG 10 001 Funding Number: RFA AG 10 001 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CK 09 002", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.